IOVANCE BIOTHERAPEUTICS, INC. Quarterly Debt-to-equity in % from Q3 2019 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Iovance Biotherapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2019 to Q3 2024.
  • Iovance Biotherapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 28.5 %, a 1.39% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 28.5 +0.39 +1.39% Sep 30, 2024
Q2 2024 28.1 -2.48 -8.12% Jun 30, 2024
Q1 2024 29.5 -0.63 -2.09% Mar 31, 2024
Q4 2023 28.4 -3.11 -9.88% Dec 31, 2023
Q3 2023 28.1 -1.1 -3.77% Sep 30, 2023
Q2 2023 30.5 +6.07 +24.8% Jun 30, 2023
Q1 2023 30.1 +9.35 +45% Mar 31, 2023
Q4 2022 31.5 +13.1 +71.6% Dec 31, 2022
Q3 2022 29.2 +12.7 +76.5% Sep 30, 2022
Q2 2022 24.5 +10.2 +71.4% Jun 30, 2022
Q1 2022 20.8 +8.35 +67.2% Mar 31, 2022
Q4 2021 18.4 +6.26 +51.8% Dec 31, 2021
Q3 2021 16.5 +5.58 +51% Sep 30, 2021
Q2 2021 14.3 +2.76 +24% Jun 30, 2021
Q1 2021 12.4 -0.69 -5.26% Mar 31, 2021
Q4 2020 12.1 +1.91 +18.7% Dec 31, 2020
Q3 2020 11 +3.67 +50.4% Sep 30, 2020
Q2 2020 11.5 Jun 30, 2020
Q1 2020 13.1 Mar 31, 2020
Q4 2019 10.2 Dec 31, 2019
Q3 2019 7.28 Sep 30, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.